A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis

Journal of Neuroimmunology

Volumn 194, Issue 1-2, 2008, Pages 89-96

  Fuchs, Sara ^a   Feferman, Tali ^a   Meidler, Roberto ^b   Margalit, Raanan ^a   Sicsic, Camille ^c   Wang, Ningshan ^a   Zhu, Kai Yun ^a   Brenner, Talma ^c   Laub, Orgad ^b   Souroujon, Miriam C ^a,d  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Omrix Biopharmaceuticals   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

Disease specific anti antibodies; Experimental autoimmune myasthenia gravis (EAMG); IVIG (intravenous immunoglobulin) therapy; Myasthenia gravis (MG)

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CROSS REACTION; DRUG EFFECT; DRUG MECHANISM; FRACTIONATION; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CHROMATOGRAPHY, AFFINITY; FREUND'S ADJUVANT; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RATS; SPECIES SPECIFICITY;

EID: 39849095842     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.11.020     Document Type: Article

References (35)

1. Achiron A., Mor F., Margalit R., Cohen I.R., Lider O., and Miron S. Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. J. Autoimmun. 15 (2000) 323-330
2. Aharonov A., Tarrab-Hazdai R., Silman I., and Fuchs S. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry 14 (1977) 129-137
3. Bayary J., Dasgupta S., Misra N., Ephrem A., Van Huyen J.P., Delignat S., Hassan G., Caligiuri G., Nicoletti A., Lacroix-Desmazes S., Kazatchkine M.D., and Kaveri S. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int. Immunopharmacol. 6 (2006) 528-534
4. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., and Kaveri S.V. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat. Clin. Pract. Rheumatol. 3 (2007) 262-272
5. Buchwald B., Ahangari R., Weishaupt A., and Toyka K.V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann. Neurol. 51 (2002) 673-680
6. Buchwald B., Ahangari R., Weishaupt A., and Toyka K.V. Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins. Muscle Nerve 31 (2005) 487-494
7. Bussel J.B., and Hilgartner M.W. The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease. Br. J. Haematol. 56 (1984) 1-7
8. Dalakas M.C. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol. Ther. 102 (2004) 177-193
9. Durelli L., and Isoardo G. High-dose intravenous immunoglobulin treatment of multiple sclerosis. Neurol. Sci. 23 Suppl 1 (2002) S39-S48
10. Edan G., and Landgraf F. Experience with intravenous immunoglobulin in myasthenia gravis: a review. J. Neurol. Neurosurg. Psychiatry 57 (1994) 55-56
11. Fateh-Moghadam A., Wick M., Besinger U., and Geursen R.G. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1 (1984) 848-849
12. Ferrero B., and Durelli L. High-dose intravenous immunoglobulin G treatment of myasthenia gravis. Neurol. Sci. 23 Suppl 1 (2002) S9-S24
13. Gajdos P., Outin H., Elkharrat D., Brunel D., de Rohan-Chabot P., Raphael J.C., Goulon M., Goulon-Goeau C., and Morel E. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1 (1984) 406-407
14. Gajdos P., Chevret S., Clair B., Tranchant C., and Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol. 41 (1997) 789-796
15. Gold R., Stangel M., and Dalakas M.C. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat. Clin. Pract. Neurol. 3 (2007) 36-44
16. Hughes R.A. Systematic reviews of treatment for inflammatory demyelinating neuropathy. J. Anat. 200 (2002) 331-339
17. Im S.H., Barchan D., Fuchs S., and Souroujon M.C. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J. Clin. Invest. 104 (1999) 1723-1730
18. Jia J., and Pollock M. Treatment of rats with experimental allergic neuritis using high dose immunoglobulin. Chin Med J (Engl) 113 (2000) 1096-1099
19. Jorgensen S.H., and Sorensen P.S. Intravenous immunonoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J. Neurol. Sci. 233 (2005) 61-65
20. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673
21. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345 (2001) 747-755
22. Lemieux R., Bazin R., and Neron S. Therapeutic intravenous immunoglobulins. Mol. Immunol. 42 (2005) 839-848
23. Lennon V.A., Lambert E.H., Leiby K.R., Okarma T.B., and Talib S. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 146 (1991) 2245-2248
24. Pashov A., Dubey C., Kaveri S.V., Lectard B., Huang Y.M., Kazatchkine M.D., and Bellon B. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur. J. Immunol. 28 (1998) 1823-1831
25. Pyne D., Ehrenstein M., and Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology (Oxford) 41 (2002) 367-374
26. Rutter A., and Luger T.A. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Curr. Opin. Investig. Drugs 3 (2002) 713-719
27. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
28. Saoudi A., Hurez V., de Kozak Y., Kuhn J., Kaveri S.V., Kazatchkine M.D., Druet P., and Bellon B. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int. Immunol. 5 (1993) 1559-1567
29. Shoenfeld Y., Rauova L., Gilburd B., Kvapil F., Goldberg I., Kopolovic J., Rovensky J., and Blank M. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immunol. 14 (2002) 1303-1311
30. Souroujon M.C., Barchan D., and Fuchs S. Analysis and modulation of the immune response of mice to acetylcholine receptor by anti-idiotypes. Immunol. Lett. 9 (1985) 331-336
31. Souroujon M.C., and Fuchs S. Idiotypes and anti-idiotypes in experimental autoimmune myasthenia gravis. Ann. N. Y. Acad. Sci. 475 (1986) 81-93
32. Vassilev T., Yamamoto M., Aissaoui A., Bonnin E., Berrih-Aknin S., Kazatchkine M.D., and Kaveri S.V. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur. J. Immunol. 29 (1999) 2436-2442
33. Wada J., Shintani N., Kikutani K., Nakae T., Yamauchi T., and Takechi K. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin. Exp. Immunol. 124 (2001) 282-289
34. Weishaupt A., Kuhlmann T., Schonrock L.M., Toyka K.V., Bruck W., and Gold R. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Acta Neuropathol. (Berl) 104 (2002) 385-390
35. Zhu K.Y., Feferman T., Maiti P.K., Souroujon M.C., and Fuchs S. Intravenous immunoglobulin suppresses experimental myasthenia gravis: Immunological mechanisms. J. Neuroimmunol. 176 (2006) 187-197